NCT00788177UnknownPhase 3
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration (SUMANA)
Klinikum Ludwigshafen2 sites in 1 country10 target enrollmentStarted: November 1, 2008Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- Enrollment
- 10
- Locations
- 2
- Primary Endpoint
- Proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks
Study Overview
Brief Summary
The purpose of this study is to assess the efficacy of pegaptanib (Macugen®) for neovascular (exudative) age-related macular degeneration (AMD) when the first dose is administered to the submacular space instead of vitreous body in cases when previous state-of-the-art treatment for the AMD was deemed ineffective.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 50 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adults aged 50 years and older with neovascular AMD proven by FA
- •Patients who at baseline
- •Have a BCVA letter score in the study eye between 20/40 to 20/320 using an ETDRS chart measured at 4 meters or Snellen equivalent
- •Have a CNV lesion of any type in the study eye with the following characteristics as determined by fluorescein angiography:
- •Evidence that CNV extends under the geometric center of the foveal avascular zone.
- •Previous state-of-the-art therapy for the disease is deemed ineffective with following characteristics are given:
- •Loss of visual acuity (2 or more Snellen lines) in the previous 3 months defined as either OR
- •≥10% increase in the lesion diameter as assessed by fluorescein angiography in the previous 3 months
- •Ability of subject to understand character and individual consequences of clinical trial.
- •Signed and dated informed consent of the subject must be available before start of any specific trial procedures.
- •Women with childbearing potential practicing a medically accepted contraception (negative pregnancy test result, serum or urine at trial entry).
Exclusion Criteria
- •Subjects presenting with any of the following criteria will not be included in the trial:
- •Have a relevant ocular disease which may be associated with increased intraocular VEGF levels (namely uveitis, neovascular glaucoma, diabetic retinopathy, diabetic maculopathy, ocular ischemic syndrome, retinal vessel occlusion)
- •Had previous vitrectomy surgery for whatsoever reason
- •Are not pseudophakic
- •Have a >50% area of scarring of the whole CNV lesion size as seen in FA
- •Arterial hypertension refractory to medical treatment
- •Pregnancy and lactation.
- •History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.
- •Participation in other clinical trials during the present clinical trial or within the last 3 months.
- •Medical or psychological condition that would not permit completion of the trial or signing of informed consent.
- •Suspected or present ocular or periocular infection
Outcomes
Primary Outcomes
Proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks
Time Frame: 54 weeks
Mean change from baseline in total size of lesion and total size of CNV at 12, 24 and 54 weeks
Time Frame: week 24 and 54
Secondary Outcomes
- Changes in best corrected visual acuity (BCVA) from baseline at 54 weeks(54 weeks)
- Mean change from baseline in at week 12 and 24(week 12 and 24)
- Proportion of patients who gain ≥ 5, 10, 15 letters of BCVA from baseline at week 24 and 54(week 24 and 54)
- Proportion of patients who lose less than 15 letters of BCVA from baseline at week 24 and 54(week 24 and 54)
- Change in area of leakage at 12, 24 and 54 weeks(weeks 12, 24 and 54)
- Mean change in retinal thickness by OCT at center of fovea at 12, 24 and 54 weeks(weeks 12, 24 and 54)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Subretinal Macugen for neovascular age-related macular degeneration (SUMANA) - SUMANAeovascular (exudative) age-related macular degenerationMedDRA version: 9.1Level: LLTClassification code 10015902Term: Exudative senile macular degeneration of retinaEUCTR2007-006290-90-DESociety (Institute) for clinical research
Completed
Not Applicable
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.Neovascular Age-related Macular DegenerationNCT00549055Pfizer38
Completed
Phase 2
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular DegenerationMacular DegenerationNCT02181517Allergan25
Completed
Phase 1
A Pilot Study for the Treatment of Iris Neovascularization With MacugenIris NeovascularizationDiabetic RetinopathyNCT00295828Hermann Eye Center10
Active, not recruiting
Not Applicable
Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin)neovascular age-related macular degenerationEUCTR2006-001914-34-DEBert Mueller, Dep. Ophthalmology